Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Ther Drug Monit. 2016 Dec;38(6):728–737. doi: 10.1097/FTD.0000000000000354

Figure 2.

Figure 2

Percentage of patients developing ≥1 adverse event or remaining seizure-free within daily average phenytoin concentration intervals. A) Total phenytoin; B) Free phenytoin.